Snapshot from Sep 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial

Omega-3 Aspirin Trial for Periodontitis

Analysis based on 6 articles · First reported Aug 11, 2026 · Last updated Sep 04, 2026

Sentiment
30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The trial could influence periodontal treatment protocols and reduce antibiotic use, potentially impacting pharmaceutical sales of amoxicillin and metronidazole. It may also boost interest in omega-3 and aspirin combination therapies, though clinical adoption is years away pending further trials.

Pharmaceuticals Dental care Healthcare

A randomized controlled trial published in the Journal of Periodontology found that a combination of omega-3 fatty acids and low-dose aspirin was nearly as effective as antibiotics (amoxicillin and metronidazole) in treating severe periodontitis. The study, conducted by researchers from Albert Einstein Israelite Hospital, Guarulhos University, University of Taubate, University of São Paulo, and Harvard University, enrolled 109 patients with advanced gum disease. All received standard deep cleaning, then were divided into four groups: placebo, antibiotics for 14 days, omega-3 plus aspirin for six months, or both. After one year, 58% of the antibiotic group and 57.7% of the omega-3/aspirin group achieved the clinical target of no more than four deep pockets, compared to only 23.1% in the placebo group. Combining both treatments provided no additional benefit. The benefits persisted six months after stopping supplements. The findings suggest a potential antibiotic-sparing alternative, especially for patients who cannot tolerate antibiotics. However, researchers caution that this is a single small trial and not yet a routine replacement. Aspirin carries bleeding risks, and larger studies in diverse populations are needed.

priv
Lead research institution; positive publicity from successful trial.
Importance 70.0 Sentiment 20.0
per
Lead researcher; expressed surprise at similar efficacy.
Importance 60.0 Sentiment 10.0
per
Co-author; emphasized antibiotic resistance benefits.
Importance 50.0 Sentiment 10.0
priv
Collaborating institution; enhanced research reputation.
Importance 40.0 Sentiment 10.0
priv
Collaborating institution; contributed to study.
Importance 40.0 Sentiment 10.0
govactor
Funded the study; positive research outcome.
Importance 30.0 Sentiment 5.0
ngo
Cited as classifying antimicrobial resistance as a global threat.
Importance 20.0 Sentiment 0.0
ngo
Mentioned as a source for periodontitis information.
Importance 10.0 Sentiment 0.0
govactor
Cited for guidance against routine aspirin use in older adults.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.